Lantern Pharma's LP-300 Shows Promising PFS Benefit in EGFR-Mutant Lung Cancer Patients

Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company, announced updated Phase 2 HARMONIC trial data demonstrating that LP-300, in combination with carboplatin and pemetrexed, provided a progression-free survival (PFS) benefit that increased with treatment duration in patients with EGFR Exon 21 L858R-mutant non-small cell lung cancer (NSCLC) who had progressed following tyrosine kinase inhibitor (TKI) therapy. The emerging data showed a median PFS of 8.9 months among L858R patients treated through up to six cycles, compared with 8.4 months across the overall L858R cohort, while maintaining an exceptionally clean safety and tolerability profile. These results supported a recently FDA-cleared protocol amendment extending LP-300 dosing from six to eight cycles.

The HARMONIC trial is evaluating LP-300 in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. The company highlighted that the PFS benefit increased with longer treatment duration, suggesting that extended dosing may further improve outcomes. LP-300 is a cisplatin/ethacraplatin analog designed to overcome resistance mechanisms. The safety profile remained favorable, with no new safety signals observed.

Lantern Pharma leverages its proprietary RADR platform, an AI and machine learning system, to transform cancer therapy development. The company's pipeline includes LP-184, an acylfulvene compound for solid tumors and pediatric CNS cancers through its subsidiary Starlight Therapeutics, and LP-284, a TC-NER targeting compound for hematologic and solid tumors. Additionally, Lantern recently commercialized withZeta.ai, a multi-agentic AI co-scientist platform available as a subscription-based research tool for the global biomedical community, representing a new revenue stream.

The full press release can be accessed at https://ibn.fm/uaAUc. For more information about Lantern Pharma, visit their newsroom at https://ibn.fm/LTRN.

The implications of these data are significant for patients with EGFR L858R-mutant NSCLC, a population with limited options after TKI failure. The extended dosing protocol could lead to improved survival outcomes, and the clean safety profile suggests LP-300 may be a well-tolerated addition to standard chemotherapy. Lantern's AI-driven approach, exemplified by RADR and withZeta.ai, underscores the growing role of computational methods in identifying patient subgroups most likely to benefit from targeted therapies.